More about Jubilant Ingrevia Limited
Fundamentals for Jubilant Ingrevia Limited
Regulatory Filings for Jubilant Ingrevia Limited
Defence Profits Reach Dharavi's Machinists
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
Fundamentals for Jubilant Ingrevia Limited
Business Operations:
Sector: Basic MaterialsIndustry: Specialty Chemicals
Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Revenue projections:
JUBLINGREA's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 30.141836 |
| debtToEquity | 26.510000 |
| earningsGrowth | -0.323000 |
| revenueGrowth | -0.005000 |
| grossMargins | 0.473820 |
| operatingMargins | 0.077560 |
| trailingEps | 16.770000 |
| forwardEps | 23.425910 |
JUBLINGREA's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.
JUBLINGREA's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
JUBLINGREA's negative gross and operating margins point to financial difficulties, as the company is unable to generate profit from its core operations or production. This could signal broader problems in cost management or declining sales.
JUBLINGREA's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in JUBLINGREA's earnings potential, with forecasts indicating better financial performance than in the prior year.
Price projections:
The stock price of Jubilant Ingrevia Limited has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.
Insider Transactions:
2 transactions were made to sell JUBLINGREA shares, with market price of 686.4500122070312.JUBLINGREA saw 20 buying transactions, each while market price hovered at 644.4275024414062.The current trend of more sells at JUBLINGREA's price levels may signal a potential decline. If this selling pressure continues, it could indicate investor pessimism, leading to more price drops in the future.
Recommendation changes over time:
A recent buy bias from analysts toward JUBLINGREA indicates strong confidence in the stock's future performance. This could encourage investors to park their money in JUBLINGREA, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy